Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies

Trial Profile

A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BB-401 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Benitec Biopharma
  • Most Recent Events

    • 21 Dec 2018 According to a Benitec Biopharma media release, Benitecs scientific and clinical teams continue to evaluate the interim analysis data of stage 1. However, based on the initial analysis, the ORR required to support continued patient enrollment was not achieved. The teams will continue with patient follow-up of stage 1 patients and additional details will be disclosed following the completion of the comprehensive analyses of the clinical data derived from ongoing patient follow-up.
    • 21 Dec 2018 According to a Benitec Biopharma media release, an interim analysis was recently conducted to evaluate the objective response rate observed for the initial 12-patient cohort treated in stage 1 of this study.
    • 07 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top